174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology - United States
doi 10.1016/s1556-0864(16)30284-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE
Multidisciplinary
2014English

Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

P2.13-04 Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Crizotinib: A Multicenter Cohort Retrospective Study.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared With Chemotherapy in Previously Treated Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2014English

Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer With ALK-rearrangement: A Brief Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Feasibility of Continuing Crizotinib Therapy After RECIST-PD in Advanced Non-Small Cell Lung Cancer Patients With ALK/ROS-1 Mutations

Journal of Cancer
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy